mosquitoborn
japanes
enceph
viru
jev
caus
seriou
ill
worldwid
associ
high
morbid
mortal
current
effect
drug
approv
treatment
jev
infect
drugrepurpos
screen
altern
approach
discov
potenti
antivir
agent
studi
highcont
screen
hc
natur
extract
librari
perform
two
hit
fdaapprov
na
k
atpas
inhibitor
ouabain
digoxin
identifi
robust
effici
jev
infect
select
index
result
indic
ouabain
digoxin
block
jev
infect
replic
stage
target
na
k
atpas
furthermor
proven
ouabain
significantli
reduc
morbid
mortal
caus
jev
balbc
mous
model
work
demonstr
na
k
atpas
could
serv
target
treatment
jev
infect
ouabain
potenti
develop
effect
antijev
drug
optim
hc
assay
condit
hc
assayoptim
condit
contain
cell
densiti
infect
dose
assay
endpoint
assay
condit
hc
optim
follow
cell
densiti
cell
per
plate
multipl
infect
moi
endpoint
h
postinfect
signaltobas
sb
ratio
coeffici
variat
cv
z
factor
respect
demonstr
assay
robust
reproduct
largescal
screen
novel
antivir
compound
jev
infect
hc
assay
drug
librari
screen
reveal
novel
target
inhibitor
jev
infect
immunofluoresc
assay
ifa
base
hc
assay
perform
screen
librari
natur
extract
antijev
activ
fig
tabl
shown
fig
c
compound
select
second
screen
solubl
dimethyl
sulfoxid
dmso
room
temperatur
absenc
obviou
cytotox
vero
cell
compound
exert
inhibit
jev
defin
prime
candid
base
criterion
compound
select
screen
reconfirm
result
carri
use
prime
candid
broader
concentr
rang
eight
hit
compound
select
base
concentrationdepend
inhibitori
effect
cell
viabil
fig
b
among
compound
ouabain
digoxin
subject
investig
high
select
index
si
defin
cytotox
concentr
cc
inhibitori
concentr
ic
similar
mechan
name
cardiac
glycosid
compound
act
inhibitor
na
k
atpas
respect
infect
vero
cell
digoxin
nm
ouabain
nm
display
inhibit
rate
abil
block
viru
reduc
decreas
concentr
fig
similarli
reproduct
could
greatli
inhibit
concentr
digoxin
ouabain
reach
nm
nm
respect
simultan
fluoresc
signal
increas
diminish
drug
concentr
fig
condit
infect
ouabain
digoxin
robustli
inhibit
viru
product
plaqu
assay
reduct
approxim
log
unit
highest
concentr
fig
e
sharp
decreas
jev
rna
level
also
detect
quantit
revers
transcript
pcr
qrtpcr
assay
particular
attenu
rna
level
strain
highdos
middledos
lowdosetr
group
indic
strong
inhibit
viral
replic
fig
f
inhibitori
effect
two
compound
infect
also
evalu
cell
cell
line
jevinfect
vero
cell
plaqu
assay
perform
detect
viral
titer
dosedepend
antijev
effect
similarli
observ
two
cell
line
fig
j
ouabain
digoxin
inhibit
jev
infect
viral
rna
synthesi
determin
cellular
process
drug
target
timeofaddit
experi
perform
fig
shown
fig
neither
digoxin
ouabain
show
suppress
jev
virucid
treatment
pretreat
howev
ouabain
show
robust
inhibit
jev
treatment
importantli
ad
posttreat
ouabain
digoxin
exert
full
inhibitori
effect
jev
infect
suggest
viral
replic
main
stage
drug
show
inhibitori
activ
confirm
hypothesi
cell
electropor
jev
replicon
treat
indic
concentr
ouabain
digoxin
reveal
result
indic
drug
inhibit
jev
rna
synthesi
dosedepend
manner
neither
drug
inhibit
initi
translat
replicon
rna
confirm
drug
inhibit
jev
infect
replic
stage
jev
inhibit
ouabain
digoxin
occur
via
na
k
atpas
na
k
atpas
target
cardiac
glycosid
found
date
confirm
whether
jev
inhibit
occur
via
blockad
na
k
atpas
infect
cell
treat
dmso
two
compound
presenc
increas
nacl
kcl
two
compound
inhibit
jev
doserespons
manner
furthermor
concentr
digoxin
jev
inhibit
reduc
decreas
nacl
fig
increas
kcl
fig
experiment
condit
result
ouabain
action
consist
digoxin
fig
indic
jevinhibit
effect
compound
posit
correl
extracellular
nacl
invers
correl
kcl
result
confirm
ouabain
digoxin
exert
antivir
effect
target
na
k
atpas
ouabain
protect
jev
infectioninduc
lethal
vivo
ouabain
exhibit
stronger
inhibitori
activ
jev
infect
examin
protect
effect
ouabain
jevinduc
lethal
use
balbc
mous
anticip
mice
jevinfect
vehicletr
group
start
show
symptom
relat
protect
effect
viral
load
histopatholog
chang
mous
brain
viral
titer
determin
mous
brain
section
collect
assay
day
postinfect
result
indic
progress
diseas
ouabain
treatment
significantli
reduc
viral
load
infect
mice
compar
untreat
infect
mice
notabl
plaqu
form
ouabaintr
group
day
postinfect
fig
similarli
appar
damag
brain
includ
mening
perivascular
cuf
vacuolar
degener
observ
jevinfect
vehicletr
group
day
postinfect
ouabain
treatment
remark
allevi
phenomena
fig
result
indic
allevi
histopatholog
chang
accompani
reduct
viral
load
well
reduct
mortal
rate
confirm
cur
effect
ouabain
viral
enceph
viral
load
brain
blood
spleen
also
evalu
earli
stage
infect
shown
fig
day
postinfect
viral
titer
brain
almost
undetect
ouabain
exhibit
littl
effect
viral
titer
brain
preclin
stage
accordingli
ouabain
littl
effect
decreas
viral
titer
blood
spleen
earlier
time
point
mostli
due
detect
viral
genom
copi
number
low
compar
notabl
titer
blood
decreas
sharpli
day
day
postinfect
line
characterist
viremia
caus
jev
result
indic
ouabain
could
allevi
histopatholog
chang
reduc
viral
load
brain
thu
protect
mice
jevinduc
lethal
confirm
cur
effect
ouabain
viral
enceph
anxiolyt
drug
target
peripher
benzodiazepin
receptor
reduc
jev
infect
vitro
drug
screen
repurpos
becom
use
approach
identifi
antivir
drug
explor
novel
molecular
target
studi
viru
pathogenesi
address
urgent
need
antijev
therapi
present
librari
natur
extract
check
abil
inhibit
jev
infect
highcont
screen
assay
design
could
identifi
compound
inhibit
jev
viral
entri
translat
rna
synthesi
studi
eight
hit
compound
si
index
greater
found
exert
inhibitori
effect
jev
among
eight
compound
previous
report
possess
wide
spectrum
pharmacolog
effect
includ
antivir
activ
moreov
compound
lycorin
emodin
procyanidin
proven
effect
inhibit
flaviviru
hcv
infect
via
differ
mechan
result
demonstr
hc
assay
effect
credibl
top
two
compound
fdaapprov
na
k
atpas
inhibitor
ouabain
digoxin
cardiac
glycosid
similar
chemic
structur
use
treatment
cardiac
arrhythmia
hypotens
year
recent
ouabain
digoxin
proven
inhibit
differ
kind
virus
includ
envelop
virus
coronavirus
nonenvelop
virus
reovirus
dna
virus
human
cytomegaloviru
positivesens
rna
virus
chikungunya
viru
negativesens
rna
virus
lymphocyt
choriomening
viru
lcmv
notabl
tri
select
drugresist
variant
serial
passag
jev
use
increas
concentr
digoxin
ouabain
respect
howev
adapt
mutant
found
passag
either
drug
result
suggest
drug
might
exert
antivir
effect
target
cellular
protein
viral
protein
make
barrier
resist
difficult
overcom
cardiac
glycosid
act
via
inhibit
sodiumpotassium
ion
pump
lead
chang
intracellular
concentr
sodium
potassium
calcium
shown
play
essenti
role
mani
cellular
biosynthet
signal
vesicular
sort
pathway
studi
ouabain
exhibit
therapeut
effect
jev
infect
adult
mous
model
decreas
viral
load
allevi
patholog
injuri
brain
significantli
improv
surviv
rate
jevinfect
mice
propos
two
mechan
may
contribut
antivir
effect
first
ouabain
may
block
jev
infect
induc
cellular
stress
respons
ouabain
treatment
mammalian
cell
caus
interact
inositol
receptor
na
k
atpas
induc
calcium
oscil
activ
calciumdepend
transcript
factor
nfb
activ
protein
evid
suggest
cardiac
glycosid
mediat
inflammatori
process
via
activ
phosphoinositid
pathway
srcmitogenactiv
protein
kinas
pathway
signal
pathway
also
caus
activ
nfb
mani
gene
express
elicit
activ
nfb
includ
innat
immun
respons
growth
differenti
stimul
antivir
state
might
block
jev
infect
end
second
jev
could
replic
central
nervou
system
cn
infect
result
breakdown
bloodbrain
barrier
bbb
along
influx
inflammatori
cell
breakdown
bbb
caus
jev
infect
may
allow
bbbnonpermiss
ouabain
enter
brain
bind
murin
atpas
isoform
inhibit
viral
replic
neuron
togeth
find
provid
valuabl
inform
may
use
futur
clinic
trial
examin
effect
ouabain
jev
infect
moreov
result
indic
atpas
promis
pharmacolog
target
jev
infect
administ
ouabain
mgkg
bodi
weight
vehicl
control
everi
day
consecut
day
mice
sacrif
day
depend
experiment
design
blood
spleen
brain
sampl
collect
plaqu
assay
qrtpcr
histopatholog
investig
vectra
ss
perkinelm
viral
burden
determin
plaqu
assay
sampl
weigh
homogen
l
pb
homogen
clarifi
centrifug
g
min
dilut
serial
prior
infect
cell
viral
titer
adjust
sampl
volum
tissu
weight
calcul
titer
pfug
tissu
sampl
blood
jevinfect
mice
extract
rnaprep
pure
tissu
kit
tiangen
catalog
rnaprep
pure
blood
kit
tiangen
catalog
respect
jev
rna
level
determin
onestep
qrtpcr
abi
realtim
pcr
system
use
standard
cycl
condit
viral
burden
calcul
standard
curv
produc
use
serial
dilut
plasmid
carri
infecti
clone
histopatholog
investig
brain
tissu
collect
mice
fix
paraformaldehyd
hematoxylineosin
stain
protocol
follow
tissu
stain
statist
analysi
student
test
log
rank
test
use
evalu
statist
signific
differ
valu
p
consid
statist
signific
supplement
materi
avail
onlin
supplement
file
xlsx
file
mb
